Fibromyalgia: Knowns, unknowns, and current treatment

Bulletin of the NYU Hospital for Joint Diseases

Volumn 68, Issue 3, 2010, Pages 157-61

  Solitar, Bruce M ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOSTEROID; CYCLOBENZAPRINE; DULOXETINE; FLUOXETINE; GABAPENTIN; IBUPROFEN; MILNACIPRAN; MUSCLE RELAXANT AGENT; NALTREXONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE DERIVATIVE; OXYBATE SODIUM; PARACETAMOL; PLACEBO; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TIZANIDINE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; BACKACHE; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; DIABETIC NEUROPATHY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; FATIGUE; FIBROMYALGIA; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC ANALYSIS; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERSOMNOLENCE; MUSCULOSKELETAL PAIN; NAUSEA; NONHUMAN; OXIDATIVE STRESS; PAIN ASSESSMENT; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT EDUCATION; POSTHERPETIC NEURALGIA; QUALITY OF LIFE; RISK FACTOR; SEDATION; SIDE EFFECT; SOMNOLENCE; SYMPTOM; TREATMENT INDICATION; TREATMENT OUTCOME; WEIGHT GAIN; XEROSTOMIA;

AFFECT; COGNITION; FIBROMYALGIA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PAIN THRESHOLD; RISK FACTORS; SLEEP; TREATMENT OUTCOME;

EID: 78449251882     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum. 1990;33:160-72.
2. Mease, P, Arnold, LM, Bennett, R, et al. Fibromyalgia syndrome. J Rheumatol. 2007;34:1415-25.
3. Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis
4. Rheum. 1995;38:19-28.
5. Arshad A, Kong KO. Awareness and perceptions of fibromyalgia syndrome: a survey of southeast Asian rheumatologists. J Clin Rheumatol. 2007;13:59-62.
6. Bradley LA. Pathophysiology of fibromyalgia. Am J Med. 2009;122(12 Suppl):S22-30.
7. Abeles AM, Pillinger MH, Solitar BM, Abeles M. Narrative review: the pathophysiology of fibromyalgia. Ann Intern Med. 2007;146:726-34.
8. Gebhart GF. Descending modulation of pain. Neurosci Biobehav Rev. 2004;27:729-37.
9. Watkins LF, Maier SF. The pain of being sick: implications of immune-to-brain communication for understanding pain. Annu Rev Psychol. 2000;51:29-57.
10. Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum. 2002;46:1333-43.
11. Arnold LM, Hudson JI, Hess EV, et al. Family study of fibromyalgia. Arthritis Rheum. 2004;50:944-52.
12. Ablin J, Buskila D, Clauw DJ. Biomarkers in fibromyalgia. Curr Pain Headache Rep. 2009;13:343-9.
13. Harkness EF, Macfarlane GJ, Hahit E, et al. Mechanical injury and psychosocial factors in the work place predict the onset of widespread body pain: a two year prospective study among cohorts of newly employed workers. Arthritis Rheum. 2004;50:1357-9.
14. Buskila D, Neumann L, Vaisberg G, et al. Increased rates of fibromyalgia following cervical spine injury. A controlled study of 161 cases of traumatic injury. Arthritis Rheum. 1997;40:446-52.
15. Tishler M, Levy O, Maslakov I, et al. Neck injury and fibromyalgia-are they really associated? J Rheumatol. 2006 Jun;33(6):1183-5; Epub 2006 May 1.
16. Bennett R, Jones J, Turk DC, et al. An internet survey of 2,596 people with fibromyalgia. BMC Muskuloskel Disord. 2007;8:27-37.
17. Dinerman H, Steere AC. Lyme disease associated with fibromyalgia. Ann Intern Med. 1992;117:281-5.
18. Marquez J, Restrepo CS, Canida L, et al. Human immunodeficiency virus-associated rheumatic disorders in the HAART era. J Rheumatol. 2004;31:741-6.
19. Cruz BA, Catalan-Soares B, Prioietti F. Higher prevalence of fibromyalgia in patients infected with human T cell lymphotropic virus type I. J Rheumatol. 2006;33:2300-3.
20. Adak B, Tekeoglu I, Ediz L, et al. Fibromyalgia frequency in hepatitis B carriers. J Clin Rheumatol. 2005;11:157-9.
21. Rivera J, de Deigo A, Trinchet M, et al. Fibromyalgia-associated hepatitis C virus infection. Br J Rheumatol. 1997;36:981-5.
22. Buskila D, Shnaider A, Neumann L, et al. Fibromyalgia in hepatitis C virus infection. Another infectious disease relationship. Arch Intern Med. 1997;157:2497-500.
23. Haas L, Portela LV, Bohmer AE, et al. Increased plasma levels of brain derived neurotrophic factor (BDNF) in patients with fibromyalgia. Neurochem Res. 2010;35:830-4.
24. Ortancil O, Sanli A, Eryuksel R, et al. Association between serum ferritin level and fibromyalgia syndrome. Eur J Clin Nutr. 2010;64:308-12.
25. Sendur OF, Tastaban E, Turan Y, Ullman C. The relationship between serum trace element levels and clinical parameters in patients with fibromyalgia. Rheumatol Int. 2008;28:1117-21.
26. Wang H, Buchner M, Moser MT, et al. The role of IL-8 in patients with fibromyalgia: a prospective longitudinal study of 6 months. Clin J Pain. 2009;25:1-4.
27. Cordero MD, De Miguel M, Moreno Fernandez AM, et al. Mitochondrial dysfunction and mitophagy activation in blood mononuclear cells of fibromyalgia patients: implications in the pathogenesis of the disease. Arthritis Res Ther. 2010;12:R17.
28. Simms RW, Roy SH, Hrovat M, et al. Lack of association between fibromyalgia syndrome and abnormalities in muscle energy metabolism. Arthritis Rheum. 1994;37:794-800.
29. Staud R, Nagel S, Robinson ME, Price DD. Enhanced central pain processing of fibromyalgia patients is maintained by muscle afferent input: a randomized double-blind, placebocontrolled study. Pain. 2009;145:96-104.
30. Scudds RA, McCain GA, Rollman GB, Harth M. Improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline. J Rheumatol. 1989; 19(Suppl):98-103.
31. Carette S, Bell MJ, Reynolds WJ, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum. 1994;37:32-40.
32. Heymann RE, Helfenstein M, Feldman D. A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures. Clin Exp Rheumatol. 2001;19:697-702.
33. Quimby LG, Gratwick GM, Whitney CD, Block SR. A randomized trial of cyclobenzaprine for the treatment of fibromyalgia. J Rheumatol Suppl. 1989 Nov;19:140-3.
34. Ono H, Mishima A, Ono S, et al. Inhibitory effects of clonidine and tizanidine on release of substance P from slices of rat spinal cord and antagonism by alpha-adrenergic receptor antagonists. Neuropharmacology. 1991;30(6):585-9.
35. Goldenberg D, Mayskiy M, Mossey C, et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. 1996;39:1852-9.
36. Arnold LM, Hess EV, Hudson JI, et al. A randomized, placebocontrolled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med. 2002;112:191-7.
37. Anderberg UM, Marteinsdottir I, von Knorring L. Citalopram in patients with fibromyalgia- a randomized, double-blind, placebo-controlled study. Eur J Pain. 2000;4:27-35.
38. Patkar AA, Masand PS, Krulewicz S, et al. A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. Am J Med. 2007;120:448-54.
39. Abeles M, Solitar BM, Pillinger MH, Abeles AM. Update on fibromyalgia therapy. Am J Med. 2008;121:555-61.
40. Arnold LM, Clauw DJ, Wohlreich MM, et al. Efficacy of duloxetine in patients with fibromyalgia: pooled analysis of 4 placebo-controlled clinical trials. Prim Care Companion J Clin Psychiatry. 2009;11:237-44.
41. Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. J Rheumatol. 2009;36:398-409.
42. Branco JC, Zachrisson O, Perrot S, Mainguy Y. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in the treatment of fibromyalgia. J Rheumatol. 2010;37:851-9.
43. Goldenberg DL, CLauw DJ, Palmer RH, et al. Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study. Pain Med. 2010;11:180-94.
44. Mainguy Y. Functional magnetic resonance imagery (fMRI) in fibromyalgia and the response to milnacipran. Hum Psychopharmacol. 2009;24:S19-23.
45. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:1264-73.
46. Mease PJ, Russel IJ, Arnold LM, et al. A randomized, doubleblind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. Nat Clin Pract Rheumatol. 2008;4:514-5.
47. Crofford LJ, Simpson S, Young JP, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008;136:419-31.
48. Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia: a randomized, doubleblind, placebo-controlled, multicenter trial. Arthritis Rheum. 2007;56:1336-44.
49. Yunus MB, Masi AT, Aldag JC. Short term effects of ibuprofen in primary fibromyalgia syndrome: a double blind, placebo controlled trial. J Rheumatol. 1989;16:527-32.
50. Clark S, Tindall E, Bennett RM. A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis. J Rheumatol. 1985;12:980-3.
51. Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med. 2003;114:537-45.
52. Bennet RM, Schein J, Kosinski MR, et al. Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum. 2005;53:519-27.
53. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA. 2004;292:2388-95.
54. Karjalainen K, Malmivaara A, van Tulder M, et al. Multidisciplinary rehabilitation for fibromyalgia and musculoskeletal pain in working age adults. Cochrane Database Syst Rev. 2000;(2):CD001984.
55. Sim J, Adams N. Systematic review of randomized controlled trials of nonpharmacological interventions for fibromyalgia. Clin J Pain. 2002;18:324-36.
56. Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain. 2008;9:164-73.
57. Russell IJ, Perkins AT, Michalek JE, et al. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum. 2009;60:299-309.
58. Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10:663-72.